[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TNSN01114A1 - Derives d'imidazole nouveaux et compositions les contenant - Google Patents

Derives d'imidazole nouveaux et compositions les contenant

Info

Publication number
TNSN01114A1
TNSN01114A1 TNTNSN01114A TNSN01114A TNSN01114A1 TN SN01114 A1 TNSN01114 A1 TN SN01114A1 TN TNSN01114 A TNTNSN01114 A TN TNSN01114A TN SN01114 A TNSN01114 A TN SN01114A TN SN01114 A1 TNSN01114 A1 TN SN01114A1
Authority
TN
Tunisia
Prior art keywords
compositions containing
imidazole derivatives
new imidazole
compounds
new
Prior art date
Application number
TNTNSN01114A
Other languages
English (en)
Inventor
Kirk Ahlijanian Michael
Blair Cooper Christopher
John Helal Christopher
Lau Lit-Fui
Samuel Menniti Frank
Allen Sanner Mark
Ann Seymour Patricia
Villatobos Anabella
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN01114A1 publication Critical patent/TNSN01114A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE DES COMPOSES DE FORMULE 1 : DANS LAQUELLE R1, R2, R3 ET R4 REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, AYANT UNE ACTIVITE INHIBITRICE DE cdk5, cdk2, ET GSK-3 POUR LE TRAITEMENT DE DIVERSES MALADIES.
TNTNSN01114A 2000-07-31 2001-07-30 Derives d'imidazole nouveaux et compositions les contenant TNSN01114A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22172400P 2000-07-31 2000-07-31

Publications (1)

Publication Number Publication Date
TNSN01114A1 true TNSN01114A1 (fr) 2005-11-10

Family

ID=22829075

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN01114A TNSN01114A1 (fr) 2000-07-31 2001-07-30 Derives d'imidazole nouveaux et compositions les contenant

Country Status (35)

Country Link
EP (1) EP1305295A1 (fr)
JP (2) JP4166084B2 (fr)
KR (1) KR20030019644A (fr)
CN (1) CN1444567A (fr)
AP (1) AP2001002232A0 (fr)
AR (1) AR032629A1 (fr)
AU (1) AU2001270944A1 (fr)
BG (1) BG107469A (fr)
BR (1) BR0112862A (fr)
CA (1) CA2418115A1 (fr)
CR (1) CR6861A (fr)
CZ (1) CZ2003225A3 (fr)
DO (1) DOP2001000220A (fr)
EA (1) EA200300097A1 (fr)
EC (1) ECSP034445A (fr)
EE (1) EE200300049A (fr)
GT (1) GT200100147A (fr)
HR (1) HRP20030048A2 (fr)
HU (1) HUP0303069A3 (fr)
IL (1) IL153787A0 (fr)
IS (1) IS6662A (fr)
MA (1) MA26932A1 (fr)
MX (1) MXPA03000939A (fr)
NO (1) NO20030472L (fr)
NZ (1) NZ523272A (fr)
OA (1) OA12345A (fr)
PA (1) PA8523701A1 (fr)
PE (1) PE20020337A1 (fr)
PL (1) PL365134A1 (fr)
SK (1) SK1042003A3 (fr)
SV (1) SV2002000571A (fr)
TN (1) TNSN01114A1 (fr)
UY (1) UY26862A1 (fr)
WO (1) WO2002010141A1 (fr)
ZA (1) ZA200300819B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
AU2003209119A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
CA2475703C (fr) 2002-02-11 2016-12-20 Bayer Pharmaceuticals Corporation Urees aryliques a activite inhibitrice d'angiogenese
JP4662764B2 (ja) 2002-06-14 2011-03-30 メルク セローノ ソシエテ アノニム アゾールメチリデンシアニド誘導体およびそれらのタンパク質キナーゼモジュレーターとしての使用
DE10233817A1 (de) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituierte Diarylheterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
DK1626714T3 (da) 2003-05-20 2007-10-15 Bayer Pharmaceuticals Corp Dirarylurinstoffer mod sygdomme medieret af PDGFR
ME00294B (fr) 2003-07-23 2011-05-10 Bayer Pharmaceuticals Corp Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
UA83899C2 (uk) 2004-03-23 2008-08-26 Пфайзер Продактс Інк. Сполуки імідазолу для лікування нейродегенеративних розладів
JP2007535565A (ja) 2004-04-30 2007-12-06 バイエル ファーマシューティカルス コーポレーション 癌の治療に有用な置換ピラゾリル尿素誘導体
KR101052462B1 (ko) 2004-09-21 2011-07-28 아스텔라스세이야쿠 가부시키가이샤 아미노알콜 유도체
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007034326A2 (fr) * 2005-09-22 2007-03-29 Pfizer Products Inc. Composes imidazoles pour le traitement de troubles neurologiques
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0706621A2 (pt) 2006-01-18 2011-04-05 Amgen Inc composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134136A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
KR20090071662A (ko) 2006-10-21 2009-07-01 애보트 게엠베하 운트 콤파니 카게 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도
WO2009017453A1 (fr) * 2007-07-30 2009-02-05 Astrazeneca Ab Nouvelle combinaison thérapeutique d'antipsychotique et d'inhibiteur de gsk3 958
US8455648B2 (en) * 2008-04-24 2013-06-04 Abbott Gmbh & Co. Kg 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2012041814A1 (fr) 2010-09-27 2012-04-05 Abbott Gmbh & Co. Kg Composés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la glycogène synthase kinase-3
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
RU2666730C2 (ru) 2012-12-07 2018-09-12 Кемосентрикс, Инк. Диазольные лактамы
AU2013364038B2 (en) * 2012-12-21 2018-04-05 Chemocentryx, Inc. Diazole amides
US10653672B2 (en) 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
EP3662919A1 (fr) 2015-08-31 2020-06-10 Nutramax Laboratories, Inc. Compositions comprenant du magnolia, du phellodendron, de la théanine et/ou de la protéine de lactosérum
GB201605126D0 (en) * 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
KR102370704B1 (ko) 2016-04-07 2022-03-03 케모센트릭스, 인크. Pd-1 억제제 또는 pd-l1 억제제와 조합하여 ccr1 길항제를 투여하여 종양 총량을 감소시키는 방법
CN107698567B (zh) * 2017-10-25 2020-09-15 西南大学 靛红唑醇类化合物及其制备方法和医药应用
MA53096A (fr) * 2018-07-03 2021-05-12 Ifm Due Inc Composés et compositions destinés au traitement d'états pathologiques associés à une activité de sting
EP3920885A1 (fr) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Composés d'acide valproïque et agonistes wnt pour le traitement de troubles de l'oreille
GB201908424D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
US10590087B1 (en) 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
CN112250636A (zh) * 2020-11-09 2021-01-22 广西科技大学 5-氨基咪唑类化合物及其合成方法
TW202309030A (zh) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2降解劑及其用途
KR20240056726A (ko) 2021-09-01 2024-04-30 스프링웍스 테라퓨틱스, 인크. 니로가세스타트의 합성
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
US6489344B1 (en) * 1998-06-19 2002-12-03 Chiron Corporation Inhibitors of glycogen synthase kinase 3
WO2000021550A2 (fr) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methodes et compositions de traitement des maladies neurodegeneratives
CO5160260A1 (es) * 1999-02-19 2002-05-30 Lilly Co Eli Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido
DE69912808T2 (de) * 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel

Also Published As

Publication number Publication date
ECSP034445A (es) 2003-03-10
SK1042003A3 (en) 2004-05-04
CN1444567A (zh) 2003-09-24
PE20020337A1 (es) 2002-05-08
SV2002000571A (es) 2002-10-24
UY26862A1 (es) 2002-02-28
PL365134A1 (en) 2004-12-27
NZ523272A (en) 2004-08-27
AR032629A1 (es) 2003-11-19
MA26932A1 (fr) 2004-12-20
HUP0303069A2 (hu) 2004-03-01
JP2008255123A (ja) 2008-10-23
DOP2001000220A (es) 2002-05-15
CZ2003225A3 (cs) 2004-02-18
EP1305295A1 (fr) 2003-05-02
MXPA03000939A (es) 2003-06-24
HUP0303069A3 (en) 2004-04-28
HRP20030048A2 (en) 2003-04-30
KR20030019644A (ko) 2003-03-06
NO20030472D0 (no) 2003-01-30
JP4166084B2 (ja) 2008-10-15
JP2004505111A (ja) 2004-02-19
CA2418115A1 (fr) 2002-02-07
EE200300049A (et) 2004-10-15
IL153787A0 (en) 2003-07-31
ZA200300819B (en) 2004-04-20
NO20030472L (no) 2003-03-27
PA8523701A1 (es) 2002-04-25
WO2002010141A1 (fr) 2002-02-07
AP2001002232A0 (en) 2001-09-30
GT200100147A (es) 2002-06-25
OA12345A (en) 2004-04-13
BG107469A (bg) 2003-09-30
CR6861A (es) 2004-03-11
EA200300097A1 (ru) 2003-06-26
BR0112862A (pt) 2003-07-01
IS6662A (is) 2002-12-19
AU2001270944A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
TNSN01114A1 (fr) Derives d'imidazole nouveaux et compositions les contenant
TNSN01095A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX ET COMPOSITIONS LES CONTENANT
TNSN01048A1 (fr) Acides malonamiques et leurs derives, et compositions les contenant
TNSN01132A1 (fr) Derives de pyrazole nouveaux et compositions les contenant.
TNSN00036A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02014A1 (fr) Composes nouveaux agonistes de ppar et compositions les contenant
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN02010A1 (fr) Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01047A1 (fr) Procede pour la preparation de derives de piperazine nouveaux
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97198A1 (fr) Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant
TNSN01019A1 (fr) Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant
TNSN02032A1 (fr) Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant.
TNSN02011A1 (fr) Derives de pyrimidine bicycliques nouveaux, inhibiteurs de mmp, et compositions les contenant
TNSN01020A1 (fr) Derives heterocycliques benzocondenses de nicotinamide, et compositions les contenant
TNSN02037A1 (fr) Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant
TNSN00239A1 (fr) DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00169A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN01102A1 (fr) Derives de pyrazole nouveaux, procede pour leur preparation et compositions les contenant.